Ent Federal

However, drug counterfeiting has been shown that more and more introduced into the global supply chain, which threatens patient safety, ethical pharmaceutical sales, and undermines the integrity of distribution channels. Parallel trade is seen as a major contributor to the infringement and it is envisaged in the report.

In addition, the report provides a detailed account of the route to market for counterfeit and shows how companies and governments in Europe and North America are fighting against the strategic problem. It also updates readers on the latest parallel trade and anti-counterfeiting initiatives adopted worldwide, and if current efforts to curb this practice have been successful or not. The report examines new measures plans and recommends strategies that are probably best to restrict the practice.

The report also assesses the extent of parallel trade in Europe and worldwide counterfeiting with an analysis of the main producers of counterfeit goods and the fight against counterfeiting efforts currently in place.

Key findings

aec Parallel trade is a rapidly expanding global industry, now that reimportation is allowed in the United States. European parallel trade is expected to grow on the candidate countries by providing new markets in which the trade in many products on several markets.

aec Counterfeiting is prevalent in markets over drug prices in developed countries and also in the low market prices of essential drugs in developing countries.

aec Routes of drug distribution are the points of access to markets for counterfeits. Parallel trade and non-traded parallel roads are vulnerable to counterfeiting.

aec anti-counterfeiting technologies are being deployed in westernized countries, but there are issues to be resolved before widespread implementation such as standardization of protocols, reliability and validity of technology and finance stakeholders.

The main features of this report

aec Analysis of parallel trade and counterfeiting in the EU, North America, Asia and Africa. country analysis, including France, Germany, UK, USA, Spain, Netherlands, USA, Canada, China, India and other countries.
aec Assessment of drivers behind parallel trade and counterfeiting in the context of drug distribution.
aec Coverage of recent changes in regulations and legislation relating to parallel trade and counterfeiting in Europe and North America.

Use this report to

aec Understand how international markets are affected by parallel trade and counterfeiting.
aec Information on the scope of parallel trade and counterfeiting in major European territories and how imports have affected prices in North America.
aec Assess the impact of imports on the U.S. market and how fakes can enter the drug supply chain distribution.
aec show access routes to market counterfeit and why they are increasingly produced.

Discover

aec What is the process of parallel trade in Europe and North America, and why is it associated with counterfeiting?
aec What is the magnitude of parallel trade and reimportation in Europe and North America?
aec How regulation and recent legislation has changed the area of parallel trade?
aec What is the impact of online pharmacies on parallel trade and counterfeiting?
aec How countries grappling with counterfeiting and the efforts that have been implemented?


Contents:
Contents
Impact of counterfeiting and parallel trade
Pharmaceutical Distribution
Executive Summary 10
PT in Europe: a legitimate mechanism for redistributing 10
PT in North America: a growing industry border 11
Counterfeiting and.